News Releases

Mr. Wyzga brings leadership experience, including in rare diseases and cancer CAMBRIDGE, MA – July  12,  2018  –  X4 Pharmaceuticals , a clinical-stage biotechnology company developing novel  CXCR4  allosteric antagonist drug candidates designed to improve immune cell trafficking...

Dose dependent increases in absolute neutrophil and lymphocyte counts observed in all patients treated with X4P-001-RD X4P-001-RD was well tolerated and a recommended dose of future Phase 3 study has been established Interim report from the Phase 2 study presented at the 23 rd  E...

Favorable response rates and combinability demonstrated in heavily pretreated patients Results presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting CAMBRIDGE, Mass., June 2, 2018 –  X4 Pharmaceuticals, a clinical stage biotechnology company developin...

Study designed to evaluate X4P-001-RD in a rare genetic, primary immunodeficiency disease to be presented at the Annual Congress of the European Hematology Association Cambridge, MA – May 17, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel CX...

Study designed to evaluate X4P-001-IO in combination therapy to be presented at the Annual Meeting of the Association Society of Clinical Oncology Cambridge, MA – May 16, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs t...

Findings from a pilot study showed combination therapy of anti-PD-1 and CXCR4 antagonist had an acceptable safety profile with a potential to augment anti-tumor responses in patients who are non-responsive to anti-PD-1 checkpoint inhibitors alone Cambridge, MA – May 15, 2018  –  ...

Study designed to evaluate X4P-001-IO in expanded range of combination treatment settings to be presented at the Annual Meeting of the Association for Cancer Immunotherapy Cambridge, MA – May 8, 2018  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel C...

Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome Study aims to establish a genetic screening approach to aid in diagnosis of patients with WHIM syndrome NEW YORK, N.Y. and CAMBRIDGE, Mass....

Clinical data demonstrate single agent X4P-001-IO increases immune cell infiltration and activation in the tumor microenvironment (TME) Supportive preclinical data show robust anti-tumor activity of CXCR4 inhibition in aggressive murine model of melanoma CAMBRIDGE, Mass., April 1...

Cambridge, MA – March 20, 2018 –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that the company will participate in two upcoming investor con...

Cambridge, MA – March 15, 2018 –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001, the Company’s CXCR4 ant...

Cambridge, Mass., March  9, 2018 –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer...

Dose dependent increases in neutrophil and lymphocyte counts observed in all patients treated with X4P-001-RD   Preliminary results reported at ASH Annual Meeting from the open-label Phase 2 portion of the on-going Phase 2/3 study CAMBRIDGE, Mass., December 11, 2017  –  X4 Pharma...

CAMBRIDGE, Mass., November 16, 2017  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Dr. David C. Dale, MD will present the first clinica...

Proceeds Will Support Advancement of a Pivotal Study in a Rare Disease and Multiple Proof of Concept Studies in Immuno-Oncology CAMBRIDGE, Mass., November 16, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immu...

Combination of X4P-001-IO and Keytruda ®  (pemrbolizumab) further enhanced immune activation and lymphocyte infiltration into tumors   Supportive preclinical data show substantial single agent activity of CXCR4 inhibition  in aggressive model of melanoma CAMBRIDGE, Mass., Novembe...

Second presentation highlighting therapeutic benefit of CXCR4 inhibition in  pre-clinical model of melanoma will also be presented CAMBRIDGE, Mass., November 3, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve im...

Phase 1 dose escalation completed and enrollment in Phase 2 expansion continues CAMBRIDGE, Mass., October 30, 2017  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare disease...

Updated Clinical Data from Combination of X4P-001-IO and Inlyta ®  (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass., October 25, 2017  – X4 Ph...

Combination of CXCR4 inhibition plus Inlyta ®  was generally well tolerated Phase 1 dose escalation completed and enrollment in Phase 2 expansion continues CAMBRIDGE, Mass., Sept. 11, 2017  – X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhi...